Lori Wirth
洛里·沃思
MD
Associate Professor of Medicine, Harvard Medical School哈佛医学院医学副教授
👥Biography 个人简介
Leading expert in RAI-refractory thyroid cancer and systemic therapy. Pioneered the use of lenvatinib and RET/NTRK inhibitors in differentiated thyroid cancer. Has led major clinical trials establishing the standard of care for advanced thyroid malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
RAI-Refractory Thyroid Cancer
Led seminal clinical investigations of lenvatinib in radioiodine-refractory differentiated thyroid cancer, contributing to its FDA approval and establishing lenvatinib as a first-line standard of care.
Representative Works 代表性著作
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
New England Journal of Medicine (2015)
SELECT trial demonstrating significant progression-free survival benefit with lenvatinib in RAI-refractory differentiated thyroid cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 洛里·沃思 的研究动态
Follow Lori Wirth's research updates
留下邮箱，当我们发布与 Lori Wirth（Massachusetts General Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment